Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening

NCT06971276 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2026-04-28

No results posted yet for this study

Summary

The study is to test a liquid biopsy assay for screening and classifying anal dysplasia from blood.

Conditions

  • Anal Dysplasia

Sponsors & Collaborators

  • Massachusetts Eye and Ear Infirmary

    lead OTHER

Principal Investigators

  • Daniel L. Faden, M.D. · Massachusetts General Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-03
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06971276 on ClinicalTrials.gov